Lisaftoclax

DB18054InvestigationalSmall molecule

Lisaftoclax is a novel, orally active, selective and potent BCL-2 inhibitor.

Mechanism: Pharmacologically active on Apoptosis regulator Bcl-2
Curator reviewed
Formula / weight: C₄₅H₄₈ClN₇O₈S · 882.43 g/mol (avg)
Also known as: 4-(4-((6-(4-chlorophenyl)spiro(3.5)non-6-en-7-yl)methyl)-piperazin-1-yl)-n-((3-nitro-4-(((2s)-1,4-dioxan-2-ylmethyl)amino)phenyl)sulfonyl)-2-(1hpyrrolo(2,3-b)pyridin-5-yloxy)benzamide · 4-{4-{[6-(4-Chlorophenyl)spiro[3.5]non-6-en-7-yl]methyl}-piperazin-1-yl}-N-{{3-nitro-4-[((2S)-1,4-dioxan-2-ylmethyl)amino]phenyl}sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide · Benzamide, 4-(4-((6-(4-chlorophenyl)spiro(3.5)non-6-en-7-yl)methyl)-1-piperazinyl)-n-((4-(((2s)-1,4-dioxan-2-ylmethyl)amino)-3-nitrophenyl)sulfonyl)-2-(1h-pyrrolo(2,3-b)pyridin-5-yloxy)-
Code names: APG-2575

Resolves to

Compound

Structure

[O-][N+](=O)C1=CC(=CC=C1NC[C@H]1COCCO1)S(=O)(=O)NC(=O)C1=CC=C(C=C1OC1=CN=C2NC=CC2=C1)N1CCN(CC2=C(CC3(CCC3)CC2)C2=CC=C(Cl)C=C2)CC1

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

38Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Lisaftoclax, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.